In this review:
Front-line abemaciclib in HR+/HER2- advanced breast cancer
Neoadjuvant letrozole + taselisib in postmenopausal women with ER+/HER2- early breast cancer
Neoadjuvant letrozole + palbociclib vs 3rd generation chemo in minimal breast cancer
Adjuvant fulvestrant + anastrozole in postmenopausal women with HR+/HER2- early breast cancer
Outcomes in small, node-negative breast cancers
TIL levels and response to pembrolizumab in metastatic triple-negative breast cancer
Nivolumab after induction treatment in triple negative breast cancer
Adjuvant anti-HER2 therapy, treatment-induced amenorrhea and survival
Please login below to download this issue (PDF)